Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed.

1. Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.Human vaccines & immunotherapeutics · 2023
   Trial
2. A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults.Clinical and translational medicine · 2022
   Trial
3. Differences and Similarities in Protein and Nucleic Acid Structures and Their Biological Interactions.Current issues in molecular biology · 2025
   Review
4. Safety monitoring of precautionary third dose of COVID-19 vaccines in a district in Northern India.Journal of family medicine and primary care · 2024
   Article
5. Circular RNA: A promising new star of vaccine.Journal of translational internal medicine · 2023
   Article
6. Levels of SARS-COV-2 anti-spike protein receptor-binding domain (S-RBD) IgG in Indonesian-vaccinated healthcare workers: experimental research.Annals of medicine and surgery (2012) · 2023
   Article
7. HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review.Vaccines · 2023
   Review
8. Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review.International journal of molecular sciences · 2023
   Review
9. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.Human vaccines & immunotherapeutics · 2022
   Review
10. To vaccinate or not to vaccinate - BNT162b2 seroconversion rate and side effects among Polish healthcare workers.International journal of occupational medicine and environmental health · 2022
    Article
11. A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.Vaccine · 2022
    Article
12. Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.Vaccines · 2022
    Article
13. Reply to 'Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani et al.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022
    Article
14. Delta Variant: Partially Sensitive To Vaccination, but Still Worth Global Attention.Journal of translational internal medicine · 2022
    Article
15. Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection.Viruses · 2022
    Article
16. Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants.Diabetes & metabolic syndrome · 2022
    Review
17. Nano-carriers of COVID-19 vaccines: the main pillars of efficacy.Nanomedicine (London, England) · 2021
    Review
18. What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective.United European gastroenterology journal · 2021
    Review
19. Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.Cell reports · 2021
    Article
20. Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers in Shoushtar, Iran.Clinical pathology (Thousand Oaks, Ventura County, Calif.)
    Article

Corrections and comments

• Erratum for
  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.2020

Authors and funding

25 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.